Affinity DataIC50: 20nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 50nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 50nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 60nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 70nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 100nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 200nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 220nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 530nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 560nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 560nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 580nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 670nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 690nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 780nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 870nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 880nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 890nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 910nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 950nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 960nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 970nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 1.03E+3nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 1.04E+3nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 1.06E+3nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 1.07E+3nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40E+3nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 2.04E+3nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 3.42E+3nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair
Affinity DataIC50: 3.91E+3nMAssay Description:Activity on human GSK-3β was assessed using the following methods (according to Meijer et al., Chem. Biol., 2003-10:1255-1266).In a first screen...More data for this Ligand-Target Pair